Evidence map›Paper›PMID 33037595›Full record

ReviewReviews in endocrine & metabolic disorders2021

Mouse models of growth hormone insensitivity.

Jonathan Young, Stephen Bell, Yanrong Qian, Caroline Hyman, Darlene E Berryman

Open access · greenAbstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jonathan YoungDepartment of Biomedical Sciences, Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 45701, USA.ORCID 0000-0003-1770-1391
Stephen BellDepartment of Biomedical Sciences, Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 45701, USA.ORCID 0000-0001-6950-7270
Yanrong QianEdison Biotechnology Institute, Konneker Research Labs, Ohio University, Athens, OH, USA.ORCID 0000-0002-3950-2759
Caroline HymanDepartment of Biomedical Sciences, Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 45701, USA.ORCID 0000-0003-0961-7210
Darlene E BerrymanDepartment of Biomedical Sciences, Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 45701, USA. berrymad@ohio.edu.ORCID 0000-0003-4240-9229
Biotechnology Institute · USOhio University · US

Funding

Modulating Growth Hormone Action as a Target for Improved Health and LongevityR01AG059779 · NIA · OHIO UNIVERSITY ATHENS · PI John Joseph Kopchick · 2018 to 2026
$4.7M
NIA NIH HHS R01 AG059779
6 · The paper itself

Abstract

Growth hormone (GH) induces pleiotropic effects on growth and metabolism via binding and subsequent activation of the growth hormone receptor (GHR) and its downstream signaling pathways. Growth hormone insensitivity (GHI) describes a group of disorders in which there is resistance to the action of GH and resultant insulin-like growth factor I (IGF-I) deficiency. GHI is commonly due to genetic disorders of the GH receptor causing GH receptor deficiency (e.g. Laron Syndrome (LS)), decreased activation of GHR, or defects in post-receptor signaling molecules. Genetically altered mouse lines have been invaluable to better understand the physiological impact of GHI due to the ability to do invasive and longitudinal measures of metabolism, growth, and health on a whole animal or in individual tissues/cells. In the current review, the phenotype of mouse lines with GHI will be reviewed. Mouse lines to be discussed include: 1) GHR-/- mice with a gene disruption in the GHR that results in no functional GHR throughout life, also referred to as the Laron mouse, 2) mice with temporal loss of GHR (aGHRKO) starting at 6 weeks of age, 3) mice transgenic for a GHR antagonist (GHA mice), 4) mice with GHI in select tissues or cells generated via Cre-lox or related technology, and 5) assorted mice with defects in post-receptor signaling molecules. Collectively, these mouse lines have revealed an intriguing role of GH action in health, disease, and aging.

Indexed as

Human Growth HormoneLaron SyndromeAnimalsGrowth DisordersGrowth HormoneHumansInsulin-Like Growth Factor IMiceReceptors, SomatotropinGrowth HormoneHuman Growth HormoneInsulin-Like Growth Factor IReceptors, SomatotropinGHA miceGHR-/- miceGrowth hormoneGrowth hormone insensitivityGrowth hormone resistanceMouse lines

Identifiers

PMID33037595
PMCPMC7979446
OpenAlexW3092542106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.